The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia.
Ontology highlight
ABSTRACT: : Muscle wasting is a feature of the cachexia syndrome, which contributes significantly to the mortality of patients with cancer. We have previously demonstrated that miR-21 is secreted through extracellular vesicles (EV) by lung and pancreatic cancer cells and promotes JNK-dependent cell death through its binding to the TLR7 receptor in murine myoblasts. Here, we evaluate the ability of IMO-8503, a TLR7, 8, and 9 antagonist, to inhibit cancer-induced cachexia. Using EVs isolated from lung and pancreatic cancer cells and from patient plasma samples, we demonstrate that IMO-8503 inhibits cell death induced by circulating miRNAs with no significant toxicity. Intraperitoneal administration of the antagonist in a murine model for Lewis lung carcinoma (LLC-induced cachexia) strongly impaired se
SUBMITTER: Calore F
PROVIDER: S-EPMC6541227 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA